S Thijssen1, H Wildiers2, K Punie2, B Beuselinck2, P Clement2, C Remmerie2, P Berteloot3, S Han3, E Van Nieuwenhuysen3, T Van Gorp3, I Vergote3, A Smeets4, I Nevelsteen4, G Floris5, C Weltens6, J Menten6, H Janssen6, A Laenen7, P Neven3. 1. Department of Gynecological Oncology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. soetkinthijssen24@hotmail.com. 2. Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. 3. Department of Gynecological Oncology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. 4. Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium. 5. Department of Pathology, University Hospitals Leuven, Leuven, Belgium. 6. Department of Radiotherapy, University Hospitals Leuven, Leuven, Belgium. 7. Department of Biostatistics, University Hospitals Leuven, Leuven, Belgium.
Abstract
PURPOSE: In metastatic breast cancer (MBC) population treated with capecitabine monotherapy, we investigated clinical-pathological features as possible biomarkers for the oncological outcome. METHODS: Retrospective study of consecutive MBC patients treated at University Hospitals Leuven starting capecitabine between 1999 and 2017. The primary endpoint was the durable response (DR), defined as non-progressive disease for > 52 weeks. Other main endpoints were objective response rate (ORR), time to progression (TTP) and overall survival (OS). RESULTS: We included 506 patients; mean age at primary breast cancer diagnosis was 51.2 years; 18.2% had de novo MBC; 98.8% were pre-treated with taxanes and/or anthracycline. DR was reached in 11.6%. Patients with DR, as compared to those without DR, were more likely oestrogen receptor (ER) positive (91.5% vs. 76.8%, p = 0.010) at first diagnosis, had a lower incidence of lymph node (LN) involvement (35.6% vs. 49.9%, p = 0.039) before starting capecitabine, were more likely to present with metastases limited to ≤ 2 involved sites (54.2% vs. 38.5%, p = 0.020) and time from metastasis to start of capecitabine was longer (mean 3.5 vs. 2.7 years, p = 0.020). ORR was 22%. Median TTP and OS were 28 and 58 weeks, respectively. In multivariate analysis (only performed for TTP), ER positivity (hazard ratio (HR) = 0.529, p < 0.0001), HER2 negativity (HR = 0.582, p = 0.024), absence of LN (HR = 0.751, p = 0.008) and liver involvement (HR = 0.746, p = 0.013), older age at capecitabine start (HR = 0.925, p < 0.0001) and younger age at diagnosis of MBC (HR = 0.935, p = 0.001) were significant features of longer TTP. CONCLUSION: Our data display relevant clinical-pathological features associated with DR and TTP in patients receiving capecitabine monotherapy for MBC.
PURPOSE: In metastatic breast cancer (MBC) population treated with capecitabine monotherapy, we investigated clinical-pathological features as possible biomarkers for the oncological outcome. METHODS: Retrospective study of consecutive MBCpatients treated at University Hospitals Leuven starting capecitabine between 1999 and 2017. The primary endpoint was the durable response (DR), defined as non-progressive disease for > 52 weeks. Other main endpoints were objective response rate (ORR), time to progression (TTP) and overall survival (OS). RESULTS: We included 506 patients; mean age at primary breast cancer diagnosis was 51.2 years; 18.2% had de novo MBC; 98.8% were pre-treated with taxanes and/or anthracycline. DR was reached in 11.6%. Patients with DR, as compared to those without DR, were more likely oestrogen receptor (ER) positive (91.5% vs. 76.8%, p = 0.010) at first diagnosis, had a lower incidence of lymph node (LN) involvement (35.6% vs. 49.9%, p = 0.039) before starting capecitabine, were more likely to present with metastases limited to ≤ 2 involved sites (54.2% vs. 38.5%, p = 0.020) and time from metastasis to start of capecitabine was longer (mean 3.5 vs. 2.7 years, p = 0.020). ORR was 22%. Median TTP and OS were 28 and 58 weeks, respectively. In multivariate analysis (only performed for TTP), ER positivity (hazard ratio (HR) = 0.529, p < 0.0001), HER2 negativity (HR = 0.582, p = 0.024), absence of LN (HR = 0.751, p = 0.008) and liver involvement (HR = 0.746, p = 0.013), older age at capecitabine start (HR = 0.925, p < 0.0001) and younger age at diagnosis of MBC (HR = 0.935, p = 0.001) were significant features of longer TTP. CONCLUSION: Our data display relevant clinical-pathological features associated with DR and TTP in patients receiving capecitabine monotherapy for MBC.
Entities:
Keywords:
Capecitabine monotherapy; Durable response; Metastatic breast cancer; Treatment efficacy
Authors: Jung Yong Hong; Yeon Hee Park; Moon Ki Choi; Hyun Ae Jung; Su Jin Lee; Jin Seok Ahn; Young-Hyuck Im Journal: Clin Breast Cancer Date: 2015-04-23 Impact factor: 3.225
Authors: J Ettl; R G W Quek; K-H Lee; H S Rugo; S Hurvitz; A Gonçalves; L Fehrenbacher; R Yerushalmi; L A Mina; M Martin; H Roché; Y-H Im; D Markova; H Bhattacharyya; A L Hannah; W Eiermann; J L Blum; J K Litton Journal: Ann Oncol Date: 2018-09-01 Impact factor: 32.976
Authors: M Miwa; M Ura; M Nishida; N Sawada; T Ishikawa; K Mori; N Shimma; I Umeda; H Ishitsuka Journal: Eur J Cancer Date: 1998-07 Impact factor: 9.162
Authors: S-H Lee; J Lee; J Park; S H Park; K-E Lee; S I Lee; E Nam; J O Park; K Kim; C W Jung; Y S Park; S S Yoon; W K Kang; M H Lee; K Park; Y-H Im Journal: Med Oncol Date: 2004 Impact factor: 3.064
Authors: C Cauchi; N Somaiah; P F Engstrom; S Litwin; M Lopez; J Lee; M Davey; B Bove; M von Mehren Journal: Cancer Chemother Pharmacol Date: 2011-11-27 Impact factor: 3.333
Authors: Maren K Levin; Kai Wang; Roman Yelensky; Ying Cao; Corinne Ramos; Nicholas Hoke; John Pippen; Joanne L Blum; Barry Brooks; Gary Palmer; Norma Palma; Sohail Balasubramanian; Jeffrey S Ross; Joyce O'Shaughnessy Journal: Cancer Med Date: 2015-04-13 Impact factor: 4.452